XML 16 R3.htm IDEA: XBRL DOCUMENT v3.23.2
Condensed Consolidated Statements of Operations - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Revenues:        
Revenue from collaborative arrangements and other contracts $ 225,971 $ 784,395 $ 340,914 $ 983,469
Operating expenses:        
Research and development 23,743,970 56,464,885 53,920,481 112,443,496
General and administrative 13,523,098 48,456,836 27,413,708 64,410,294
Total operating expenses 37,267,068 104,921,721 81,334,189 176,853,790
Loss from operations (37,041,097) (104,137,326) (80,993,275) (175,870,321)
Other income (expense):        
Interest income 2,168,233 857,667 4,375,404 1,527,481
Interest expense (313,488) (313,488) (626,976) (626,976)
Gain (loss) on investment in affiliated entity 156,745 (934,015) 773,384 (1,471,743)
Net unrealized gain (loss) on available-for-sale equity securities 922,941 (3,967,101) 4,141,156 (8,807,742)
Other expense, net (1,427,867) (3,048) (3,853,543) (156,516)
Net loss before share in net loss of Geneos (35,534,533) (108,497,311) (76,183,850) (185,405,817)
Share in net loss of Geneos 0 0 0 (2,165,213)
Net loss $ (35,534,533) $ (108,497,311) $ (76,183,850) $ (187,571,030)
Net loss per share        
Basic (in dollars per share) $ (0.13) $ (0.46) $ (0.29) $ (0.83)
Diluted (in dollars per share) $ (0.13) $ (0.46) $ (0.29) $ (0.83)
Weighted average number of common shares outstanding        
Basic (in shares) 264,353,833 235,278,276 261,412,116 227,154,616
Diluted (in shares) 264,353,833 235,278,276 261,412,116 227,154,616